2019
DOI: 10.1002/ccr3.2000
|View full text |Cite
|
Sign up to set email alerts
|

Pulse‐steroid therapy in a 37‐year‐old man with acute motor and sensory axonal neuropathy: A case report

Abstract: Key Clinical Message We report a case of 37‐year‐old man admitted with acute motor and sensory axonal neuropathy (AMSAN) which was treated with pulse‐steroid therapy after the plasmapheresis and intravascular immunoglobulin. The improvement of the symptoms of AMSAN after pulse‐steroid therapy may represent a therapeutic alternative for this variant of Guillain‐Barré syndrome.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
0
1
1

Year Published

2021
2021
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 11 publications
0
0
1
1
Order By: Relevance
“…A systematic review of six trials with a total of 587 participants provided moderate‐quality evidence that corticosteroids alone did not significantly accelerate the recovery or affect the long‐term outcomes of patients with GBS (Hughes et al, 2016). This is in contrast to the four case reports that have independently shown positive effects of pulse steroid therapy for the management of GBS, including improved neurological outcomes and decreased complication rates (AlMohammedi et al, 2019; Beauvais & Furby, 2006; Nozaki et al, 1990; Tada et al, 2003). There currently is no definitive evidence regarding the role of pulse‐steroid therapy in the treatment of GBS, and should only be considered to be implemented as a therapy on a wider scale if future large trials show definitive evidence of it as an effective therapeutic alternative.…”
Section: Low‐cost Alternativescontrasting
confidence: 69%
“…A systematic review of six trials with a total of 587 participants provided moderate‐quality evidence that corticosteroids alone did not significantly accelerate the recovery or affect the long‐term outcomes of patients with GBS (Hughes et al, 2016). This is in contrast to the four case reports that have independently shown positive effects of pulse steroid therapy for the management of GBS, including improved neurological outcomes and decreased complication rates (AlMohammedi et al, 2019; Beauvais & Furby, 2006; Nozaki et al, 1990; Tada et al, 2003). There currently is no definitive evidence regarding the role of pulse‐steroid therapy in the treatment of GBS, and should only be considered to be implemented as a therapy on a wider scale if future large trials show definitive evidence of it as an effective therapeutic alternative.…”
Section: Low‐cost Alternativescontrasting
confidence: 69%
“…Перечисленные критерии были замечены и в нашем случае с той лишь разницей, что мышечная слабость была диффузной, с равномерным вовлечением проксимальных и дистальных отделов при отчетливой ее асимметрии (в дебюте -трипарез). Интересен также клинический случай эффективности ГКС-терапии при аксональной форме СГБ, опубликованный коллегами из Саудовской Аравии [22]. Представленная совокупность данных, ответ на терапию ГКС позволяют также думать о том, что, возможно, имел место острый дебют ХВДП при первично диагностированной острой моторно-сенсорной аксональной невропатии.…”
Section: Discussionunclassified